



US008952138B2

(12) **United States Patent**
Shultz et al.

(10) **Patent No.:** **US 8,952,138 B2**
(45) **Date of Patent:** ***Feb. 10, 2015**

(54) **REFOLDING PROTEINS USING A
CHEMICALLY CONTROLLED REDOX
STATE**

(75) Inventors: **Joseph Edward Shultz**, Santa Rosa
Valley, CA (US); **Roger Hart**, Loveland,
CO (US); **Ronald Nixon Keener, III**,
Newbury Park, CA (US)

(73) Assignee: **Amgen Inc.**, Thousand Oaks, CA (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 403 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **12/820,087**

(22) Filed: **Jun. 21, 2010**

(65) **Prior Publication Data**

US 2010/0324269 A1 Dec. 23, 2010

Related U.S. Application Data

(60) Provisional application No. 61/219,257, filed on Jun.
22, 2009.

(51) **Int. Cl.**
C07K 1/22 (2006.01)
C07K 1/113 (2006.01)

(52) **U.S. Cl.**
CPC **C07K 1/113** (2013.01)
USPC **530/413**

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,660,843	B1	12/2003	Feige et al.
6,808,902	B1	10/2004	Treuheit et al.
7,138,370	B2	11/2006	Oliner et al.
7,511,012	B2	3/2009	Han et al.
7,723,490	B2	5/2010	Treuheit et al.
2008/0214795	A1	9/2008	Ramanan et al.
2010/0267936	A1	10/2010	Treuheit et al.

FOREIGN PATENT DOCUMENTS

EP	1845103	A1	10/2007
WO	92/04382	A1	3/1992
WO	99/42486	A1	8/1999

OTHER PUBLICATIONS

Cowley, D.J., & Mackin, R.B., "Expression, purification and charac-
terization of recombinant human proinsulin," FEBS Lett 402:125-
130 (1997).

De Bernardez Clark, Eliana, et al. "Oxidative Renaturation of Hen
Egg-White Lysozyme, Folding vs aggregation." Biotechnol. Prog.
14: 47-57 (1998).

Rudolph & Lilie, "In vitro folding of inclusion body proteins,"
FASEB J. 10:49-56 (1996).

Creighton, T.E., "Renaturation of the reduced bovine pancreatic
trypsin inhibitor," J. Mol. Biol. 87:563-577 (1974).

Stöckel, Johannes, et al., "Pathway of detergent-mediated and
peptide ligand-mediated refolding of heterodimeric class II major
histocompatibility complex (MHC) molecules," Eur J Biochem
248:684-691 (1997).

St John et al., "High pressure refolding of recombinant human growth
hormone from insoluble aggregates. Structural transformations,
kinetic barriers, and energetics," J. Biol. Chem. 276(50):46856-63
(2001).

Lilie, Schwarz & Rudolph, "Advances in refolding of proteins
reduced in *E. coli*," Current Opinion in Biotechnology 9 (5):497-501
(1998).

Tran-Moseman, Schauer & Clark, "Renaturation of *Escherichia*
coli—Derived Recombinant Human Macrophage Colony-Stimulat-
ing Factor," Protein Expression & Purification 16(1):181-189 (1999).

Darby, N.J., et al., "Refolding of Bovine Pancreatic Trypsin
Inhibitor via Non-native Disulphide Intermediate," J Molecular Biol.
249(2):463-477 (1995).

Wang, Xi-De, "Perturbation of the antigen-binding site and
staphylococcal protein A-binding site of IgG before significant
changes in global conformation during denaturation: an equilibrium
study," Biochem. Prog. 14: 47-54 (1998).

Singh et al., "Solubilization and Refolding of Bacterial Inclusion
Body Proteins," J. Bioscience and Bioengineering, vol. 99(4), pp.
303-310 (2005).

DeBernadez Clark, Eliana, "Refolding of recombinant proteins,"
Current Opinion in Biotechnology, vol. 9 p. 157-163 (1998).

DuBernardez Clark, Eliana, "Protein Refolding for industrial pro-
cesses," Current Opinion in Biotechnology, vol. 12, pp. 202-207
(2001).

Javaherian, K. et al., "Laminin Modulates Morphogenic Properties of
the Collagen XVIII Endostatin Domain," J. Biol. Chem.
277(47):45211-45218, Nov. 22, 2002.

Primary Examiner — Yunsoo Kim

(74) *Attorney, Agent, or Firm* — David B. Ran

(57) **ABSTRACT**

A method of refolding proteins expressed in non-mammalian
cells present in concentrations of 2.0 g/L or higher is dis-
closed. The method comprises identifying the thiol pair ratio
and the redox buffer strength to achieve conditions under
which efficient folding at concentrations of 2.0 g/L or higher
is achieved and can be employed over a range of volumes,
including commercial scale.

24 Claims, 8 Drawing Sheets